Login Register Cart 0
Current Traditional Medicine

Current Traditional Medicine

Editor-in-Chief

ISSN (Print): 2215-0838
ISSN (Online): 2215-0846

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review of Modern and Traditional Approaches for the Management of Pulmonary Hypertension

Author(s): Anuradha Verma*, Anshika Garg, Sultan Ahmad, Saquib Haider, Babita Kumar, Ritu Chauhan, Manish K. Singh and Sambhu Charan Mondal

Volume 10, Issue 6, 2024

Published on: 22 August, 2023

Article ID: e120723218656 Pages: 15

DOI: 10.2174/2215083810666230712091733

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Research Problem: Hypertension, either high blood pressure or pulmonary hypertension, both affect the life of patients in many ways.

Research Questions: Does Pulmonary hypertension similar to high blood pressure?

Does it affect old age people or the neonatal age groups also?

What were the reasons for pulmonary hypertension?

Does pulmonary hypertension manageable with modern and traditional drugs?

Literature Review: The purpose of the literature review is to identify the targeted therapy for pulmonary hypertension and also include the plants that may be effective for the management of pulmonary hypertension.

Conclusion: The author has reviewed many targeted drugs that are presently used, and many are in research that was found effective in making the life of patients as normal as possible.

They also reviewed about 15 herbal plants which were found effective in the management of the disease.

As pulmonary hypertension is not treatable, it can only be managed by changing lifestyle and food habits; therefore, the authors emphasized reviewing the traditional approach for the management of pulmonary hypertension.

Keywords: (mPAP), pulmonary hypertension, pulmonary vascular resistance, drug therapy, cardiovascular, lung disorders.

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65(18): 1976-97.
[http://dx.doi.org/10.1016/j.jacc.2015.03.540] [PMID: 25953750]
[2]
Sonnweber T, Pizzini A, Tancevski I, Löffler-Ragg J, Weiss G. Anaemia, iron homeostasis and pulmonary hypertension: A review. Intern Emerg Med 2020; 15(4): 573-85.
[http://dx.doi.org/10.1007/s11739-020-02288-1] [PMID: 32040829]
[3]
Sysol JR, Machado RF. Classification and pathophysiology of pulmonary hypertension. Contin Cardiol Educ 2018; 4(1): 2-12.
[http://dx.doi.org/10.1002/cce2.71]
[4]
Yao L, Yang Y, He G, Ou C, Wang L, Liu K. Global proteomics deciphered novel-function of osthole against pulmonary arterial hypertension. Sci Rep 2018; 8(1): 5556.
[http://dx.doi.org/10.1038/s41598-018-23775-8] [PMID: 29615702]
[5]
Jasemi SV, Khazaei H, Aneva IY, Farzaei MH, Echeverría J. Medicinal plants and phytochemicals for the treatment of pulmonary hypertension. Front Pharmacol 2020; 11: 145.
[http://dx.doi.org/10.3389/fphar.2020.00145] [PMID: 32226378]
[6]
Lan N, Massam B, Kulkarni S, Lang C. Pulmonary arterial hypertension: Pathophysiology and treatment. Diseases 2018; 6(2): 38.
[http://dx.doi.org/10.3390/diseases6020038] [PMID: 29772649]
[7]
Bazan IS, Fares WH. Pulmonary hypertension: Diagnostic and therapeutic challenges. Ther Clin Risk Manag 2015; 11: 1221-33.
[PMID: 26316767]
[8]
Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A review. JAMA Cardiol 2016; 1(9): 1056-65.
[http://dx.doi.org/10.1001/jamacardio.2016.4471] [PMID: 27851839]
[9]
Ryan J, Dasgupta A, Huston J, Chen KH, Archer SL. Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med 2015; 93(3): 229-42.
[http://dx.doi.org/10.1007/s00109-015-1263-5] [PMID: 25672499]
[10]
Woodard TJ, Kim C, Siao FA. Review of the diagnosis and management of pulmonary arterial hypertension. US Pharm 2018; 43(3): HS10-6.
[11]
Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44(1): 14-30.
[http://dx.doi.org/10.1016/j.yjmcc.2007.09.006] [PMID: 17950310]
[12]
Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012; 302(4): L363-9.
[http://dx.doi.org/10.1152/ajplung.00212.2011] [PMID: 21964406]
[13]
Bienertova-Vasku J, Novak J, Vasku A. MicroRNAs in pulmonary arterial hypertension: Athogenesis, diagnosis and treatment. J Am Soc Hypertens 2015; 9(3): 221-34.
[http://dx.doi.org/10.1016/j.jash.2014.12.011] [PMID: 25660363]
[14]
Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: Pathogenesis and clinical management. BMJ 2018; 360: j5492.
[http://dx.doi.org/10.1136/bmj.j5492] [PMID: 29540357]
[15]
Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017; 14(10): 603-14.
[http://dx.doi.org/10.1038/nrcardio.2017.84] [PMID: 28593996]
[16]
Xiang L, Li Y, Deng X, Kosanovic D, Schermuly RT, Li X. Natural plant products in treatment of pulmonary arterial hypertension. Pulm Circ 2018; 8(3): 1-20.
[http://dx.doi.org/10.1177/2045894018784033] [PMID: 29869936]
[17]
Misumi K, Ogo T, Ueda J, et al. Development of pulmonary arterial hypertension in a patient treated with Qing-Dai (Chinese herbal medicine). Intern Med 2019; 58(3): 395-9.
[http://dx.doi.org/10.2169/internalmedicine.1523-18] [PMID: 30210129]
[18]
Prins KW, Thenappan T. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 2016; 34(3): 363.
[http://dx.doi.org/10.1016/j.ccl.2016.04.001] [PMID: 27443134]
[19]
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4(4): 306-22.
[http://dx.doi.org/10.1016/S2213-2600(15)00543-3] [PMID: 26975810]
[20]
Kopeć G, Kurzyna M, Mroczek E, et al. Characterization of patients with pulmonary arterial hypertension: Data from the polish registry of pulmonary hypertension (BNP-PL). J Clin Med 2020; 9(1): 173.
[http://dx.doi.org/10.3390/jcm9010173] [PMID: 31936377]
[21]
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801913.
[http://dx.doi.org/10.1183/13993003.01913-2018] [PMID: 30545968]
[22]
Barnett CF, Alvarez P, Park MH. Pulmonary arterial hypertension: Diagnosis and treatment. Cardiol Clin 2016; 34(3): 375-89.
[http://dx.doi.org/10.1016/j.ccl.2016.04.006] [PMID: 27443135]
[23]
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801904.
[http://dx.doi.org/10.1183/13993003.01904-2018] [PMID: 30545972]
[24]
Hoeper MM, McLaughlin VV, Dalaan AMA, Satoh T, Galiè N. Treatment of pulmonary hypertension. Lancet Respir Med 2016; 4(4): 323-36.
[http://dx.doi.org/10.1016/S2213-2600(15)00542-1] [PMID: 26975811]
[25]
Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat 2015; 120: 56-71.
[http://dx.doi.org/10.1016/j.prostaglandins.2015.04.007] [PMID: 25917921]
[26]
Corris P, Degano B. Severe pulmonary arterial hypertension: Treatment options and the bridge to transplantation. Eur Respir Rev 2014; 23(134): 488-97.
[http://dx.doi.org/10.1183/09059180.00007214] [PMID: 25445947]
[27]
Saito Y, Nakamura K, Akagi S, et al. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag 2015; 11: 265-70.
[PMID: 25999730]
[28]
Kimura M, Tamura Y, Takei M, et al. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension. PLoS One 2015; 10(4): e0121894.
[http://dx.doi.org/10.1371/journal.pone.0121894] [PMID: 25844932]
[29]
Tokunaga N, Ogawa A, Ito H, Matsubara H. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol 2016; 68(6): 542-7.
[http://dx.doi.org/10.1016/j.jjcc.2015.11.012] [PMID: 27005767]
[30]
Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342(25): 1866-70.
[http://dx.doi.org/10.1056/NEJM200006223422503] [PMID: 10861321]
[31]
Han X, Zhang Y, Dong L, et al. Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost. Respir Care 2017; 62(4): 489-96.
[http://dx.doi.org/10.4187/respcare.05280] [PMID: 28119496]
[32]
Moreno-Galdó A, Torrent-Vernetta A, de Mir Messa I, et al. Use of inhaled iloprost in children with pulmonary hypertension. Pediatr Pulmonol 2015; 50(4): 370-9.
[http://dx.doi.org/10.1002/ppul.23044] [PMID: 24729548]
[33]
Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351(16): 1655-65.
[http://dx.doi.org/10.1056/NEJMra035488] [PMID: 15483284]
[34]
Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today 2004; 40(3): 225-34.
[http://dx.doi.org/10.1358/dot.2004.40.3.820086] [PMID: 15148531]
[35]
Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care 2015; 60(6): 794-805.
[http://dx.doi.org/10.4187/respcare.03927] [PMID: 26070575]
[36]
Remodulin® (treprostinil sodium) injection. 2015. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021272s009lbl.pdf
[37]
Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: A therapeutic review. Drug Des Devel Ther 2012; 6: 19-28.
[38]
Lian TY, Jiang X, Jing ZC. Riociguat: A soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther 2017; 11: 1195-207.
[http://dx.doi.org/10.2147/DDDT.S117277] [PMID: 28458514]
[39]
Sulica R, Fenton R, Cefali F. Early observations on the use of riociguat in a large, metropolitan pulmonary arterial hypertension/chronic thromboembolic pulmonary hypertension treatment center. Cardiol Ther 2015; 4(2): 209-18.
[http://dx.doi.org/10.1007/s40119-015-0046-y] [PMID: 26411969]
[40]
Makowski CT, Rissmiller RW, Bullington WM. Riociguat: A novel new drug for treatment of pulmonary hypertension. Pharmacotherapy 2015; 35(5): 502-19.
[http://dx.doi.org/10.1002/phar.1592] [PMID: 26011143]
[41]
Frank H, Ruber K, Mlczoch J, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112(3): 714-21.
[http://dx.doi.org/10.1378/chest.112.3.714] [PMID: 9315805]
[42]
Frank H, Gurtner HP, Kneussl M, Lang I, Mlczoch J. [Aminorexinduced, plexogenic pulmonary arteriopathy: 25 years later!]. Z Kardiol 1993; 82(9): 568-72.
[PMID: 7901949]
[43]
Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115(1): 15-20.
[http://dx.doi.org/10.1182/blood-2009-09-241851] [PMID: 19880491]
[44]
Masuda Y, Miyazaki H, Kondoh M, et al. Two different forms of endothelin receptors in rat lung. FEBS Lett 1989; 257(2): 208-10.
[http://dx.doi.org/10.1016/0014-5793(89)81535-2] [PMID: 2555216]
[45]
Migneault A, Sauvageau S, Villeneuve L, et al. Chronically elevated endothelin levels reduce pulmonary vascular reactivity to nitric oxide. Am J Respir Crit Care Med 2005; 171(5): 506-13.
[http://dx.doi.org/10.1164/rccm.200403-340OC] [PMID: 15579730]
[46]
Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 2006; 24(1): 63-76.
[http://dx.doi.org/10.1111/j.1527-3466.2006.00063.x] [PMID: 16939634]
[47]
El-Saber Batiha G, Magdy Beshbishy A, G Wasef L, et al. Chemical constituents and pharmacological activities of garlic (Allium sativum L.): A review. Nutrients 2020; 12(3): 872.
[http://dx.doi.org/10.3390/nu12030872] [PMID: 32213941]
[48]
Tung NH, Hung LQ, Van Oanh H, et al. Bioactive phenolic compounds from the roots of danshen (Salvia miltiorrhiza). Natural Product Communications 2018; 13(10): 1305-7.
[49]
Hussein HJ, Hameed IH, Hadi MY. Review: Anti-microbial, anti-inflammatory effect and cardiovascular effects of garlic: Allium sativum. Res J Pharm Tech 2017; 10(11): 4069-78.
[http://dx.doi.org/10.5958/0974-360X.2017.00738.7]
[50]
Park BM, Chun H, Chae SW, Kim SH. Fermented garlic extract ameliorates monocrotaline-induced pulmonary hypertension in rats. J Funct Foods 2017; 30: 247-53.
[http://dx.doi.org/10.1016/j.jff.2017.01.024]
[51]
Meghwani H, Prabhakar P, Mohammed S, et al. Beneficial effect of Ocimum sanctum (Linn.) against monocrotaline-induced pulmonary hypertension in rats. Medicines 2018; 5(2): 34.
[http://dx.doi.org/10.3390/medicines5020034] [PMID: 29673152]
[52]
Sharma V, Chanda D. Ocimum: The Holy Basil against Cardiac Anomalies in the ocimum Genome. Cham: Springer 2018; pp. 25-36.
[http://dx.doi.org/10.1007/978-3-319-97430-9_3]
[53]
Kashif M, Ullah S. Chemical composition and minerals analysis of Hippophaerhamnoides, Azadirachta indica, Punica granatum and Ocimum sanctum leaves. World J Dairy Food Sci 2013; 8(1): 67-73.
[54]
Arora TK, Arora AK, Sachdeva MK, Rajput SK, Sharma AK. Pulmonary hypertension: Molecular aspects of current therapeutic intervention and future direction. J Cell Physiol 2018; 233(5): 3794-804.
[http://dx.doi.org/10.1002/jcp.26191] [PMID: 28926093]
[55]
Lei XL, Chiou GC. Cardiovascular pharmacology of Panax notoginseng (Burk) F.H. Chen and Salvia miltiorrhiza. Am J Chin Med 1986; 14(3-4): 145-52.
[56]
Su CY, Ming QL, Rahman K, Han T, Qin LP. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin J Nat Med 2015; 13(3): 163-82.
[http://dx.doi.org/10.1016/S1875-5364(15)30002-9] [PMID: 25835361]
[57]
Yuan T, Chen Y, Zhang H, Fang L, Du G. Salvianolic acid A, a component of Salvia miltiorrhiza, attenuates endothelial–mesenchymal transition of HPAECs induced by hypoxia. Am J Chin Med 2017; 45(6): 1185-200.
[http://dx.doi.org/10.1142/S0192415X17500653] [PMID: 28893092]
[58]
Rout SK, Dutta S, Sengupta M, Das S, Rout B. Antihypertensive therapy: The concepts of management with herbal and synthetic agents for pulmonary hypertension. Int J Pharm Sci Rev Res 2010; 3(2)
[59]
Ahmadipour B, Kalantar M, Hosseini SM. Hawthorn (Crataegus oxyacantha) Flavonoid extract as an effective medicinal plant derivative to prevent pulmonary hypertension and heart failure in broiler chickens. Kafkas Univ Vet Fak Derg 2019; 25(3): 321-8.
[60]
Ahmadipour B, Kalantar M, Schreurs NM, et al. Flavonoid bioactive compounds of hawthorn extract can promote growth, regulate electrocardiogram waves, and improve cardiac parameters of pulmonary hypertensive chickens. Poult Sci 2020; 99(2): 974-80.
[http://dx.doi.org/10.1016/j.psj.2019.10.022] [PMID: 32036989]
[61]
Isanga J, Zhang GN. Soybean bioactive components and their implications to health-a review. Food Rev Int 2008; 24(2): 252-76.
[http://dx.doi.org/10.1080/87559120801926351]
[62]
Matori H, Umar S, Nadadur RD, et al. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension 2012; 60(2): 425-30.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.191445] [PMID: 22753213]
[63]
Chen Y, Chen D, Liu S, et al. Systematic elucidation of the mechanism of genistein against pulmonary hypertension via network pharmacology approach. Int J Mol Sci 2019; 20(22): 5569.
[http://dx.doi.org/10.3390/ijms20225569] [PMID: 31703458]
[64]
Yang Y, Gao M, Wu Z, Guo Y. Genistein attenuates low temperature induced pulmonary hypertension in broiler chicks by modulating endothelial function. Eur J Pharmacol 2010; 649(1-3): 242-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.09.002] [PMID: 20854807]
[65]
Ahmadipour B, Khajali F. Expression of antioxidant genes in broiler chickens fed nettle (Urtica dioica) and its link with pulmonary hypertension. Anim Nutr 2019; 5(3): 264-9.
[http://dx.doi.org/10.1016/j.aninu.2019.04.004] [PMID: 31528728]
[66]
Chiang HM, Chen HC, Wu CS, Wu PY, Wen KC. Rhodiola plants: Chemistry and biological activity. J Food Drug Anal 2015; 23(3): 359-69.
[67]
Chen M, Cai H, Yu C, et al. Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways. Am J Transl Res 2016; 8(1): 12-27.
[PMID: 27069536]
[68]
Huang X, Zou L, Yu X, et al. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. J Mol Cell Cardiol 2015; 82(82): 153-66.
[http://dx.doi.org/10.1016/j.yjmcc.2015.03.005] [PMID: 25772255]
[69]
Venkitasamy C, Zhao L, Zhang R, Pan Z. Integrated processing technologies for food and agricultural by-products. Amsterdam: Elsevier 2019; pp. 181-216.
[70]
Shao J, Wang P, Liu A, Du X, Bai J, Chen M. Punicalagin prevents hypoxic pulmonary hypertension via anti-oxidant effects in rats. Am J Chin Med 2016; 44(4): 785-801.
[http://dx.doi.org/10.1142/S0192415X16500439]
[71]
Nik AB, Vazifedoost M, Didar Z, Hajirostamloo B. The antioxidant and physicochemical properties of microencapsulated bioactive compounds in Securigera securidaca (L) seed extract by co-crystallization Food Quality and Safety. Oxford: Academic 2019; p. 25.
[72]
Ahmadipour B. Securigera securidaca seed medicinal herb supplementation of diets improves pulmonary hypertensive response in broiler chickens reared at high altitude. J Anim Physiol Anim Nutr 2018; 102(6): 1601-7.
[http://dx.doi.org/10.1111/jpn.12981] [PMID: 30155919]
[73]
Wruss J, Waldenberger G, Huemer S, et al. Compositional characteristics of commercial beetroot products and beetroot juice prepared from seven beetroot varieties grown in Upper Austria. J Food Compos Anal 2015; 42: 46-55.
[http://dx.doi.org/10.1016/j.jfca.2015.03.005]
[74]
Clifford T, Howatson G, West D, Stevenson E. The potential benefits of red beetroot supplementation in health and disease. Nutrients 2015; 7(4): 2801-22.
[http://dx.doi.org/10.3390/nu7042801] [PMID: 25875121]
[75]
Domínguez R, Cuenca E, Maté-Muñoz J, et al. Effects of beetroot juice supplementation on ardiorespiratory endurance in athletes. A systematic review. Nutrients 2017; 9(1): 43.
[http://dx.doi.org/10.3390/nu9010043] [PMID: 28067808]
[76]
Singh B, Hathan BS. Chemical composition, functional properties and processing of beetroot-a review. Int J Sci Eng Res 2014; 5(1): 679-84.
[77]
Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008; 51(3): 784-90.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.103523] [PMID: 18250365]
[78]
Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: A systematic review and meta-analysis. J Nutr 2013; 143(6): 818-26.
[http://dx.doi.org/10.3945/jn.112.170233] [PMID: 23596162]
[79]
Wei F, Tanokura M. Organic compounds in green coffee beansCoffee in health and disease prevention. Massachusetts: Academic Press 2015; pp. 149-62.
[http://dx.doi.org/10.1016/B978-0-12-409517-5.00017-6]
[80]
Li QY, Zhu YF, Zhang M, et al. Chlorogenic acid inhibits hypoxia-induced pulmonary artery smooth muscle cells proliferation via c-Src and Shc/Grb2/ERK2 signaling pathway. Eur J Pharmacol 2015; 751: 81-8.
[http://dx.doi.org/10.1016/j.ejphar.2015.01.046] [PMID: 25666384]
[81]
Lisa J. Biotechnology of Fruit and Nut Crops (Biotechnology in Agriculture Series). Washington. Amazon 2020; 29: 703.
[82]
Prior RL, Cao G, Martin A, et al. Antioxidant capacity as influenced by total phenolic and anthocyanin content, maturity, and variety of Vaccinium species. J Agric Food Chem 1998; 46(7): 2686-93.
[http://dx.doi.org/10.1021/jf980145d]
[83]
Taruscio TG, Barney DL, Exon J. Content and profile of flavanoid and phenolic acid compounds in conjunction with the antioxidant capacity for a variety of northwest Vaccinium berries. J Agric Food Chem 2004; 52(10): 3169-76.
[http://dx.doi.org/10.1021/jf0307595] [PMID: 15137871]
[84]
Wu X, Kang J. Blueberries: Major phytochemicals and potential health effects in cardiovascular diseasesBerries: Properties, Consumption and Nutrition. New York, NY, USA: Nova Biomedical Books 2012; pp. 83-104.
[85]
Howard L, Hagar T. Berry fruit phytochemicalsBerry Fruit: Value Added Products for Health Promotion. Boca Raton, FL, USA: CRC Press 2007; pp. 73-105.
[86]
Gao L, Mazza G. Quantitation and distribution of simple and acylatedanthocyanins and other phenolics in blueberries. J Food Sci 1994; 59(5): 1057-9.
[http://dx.doi.org/10.1111/j.1365-2621.1994.tb08189.x]
[87]
Türck P, Salvador IS, Campos-Carraro C, et al. Blueberry extract improves redox balance and functional parameters in the right ventricle from rats with pulmonary arterial hypertension. Eur J Nutr 2022; 61(1): 373-86.
[http://dx.doi.org/10.1007/s00394-021-02642-9] [PMID: 34374852]
[88]
Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22(8): 999-1012.
[http://dx.doi.org/10.1002/ptr.2399] [PMID: 18618524]
[89]
Abd El-Wahab AE, Ghareeb DA, Sarhan EEM, Abu-Serie MM, El Demellawy MA, El Demellawy MA. In vitro biological assessment of berberis vulgaris and its active constituent, berberine: Antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med 2013; 13(1): 218.
[http://dx.doi.org/10.1186/1472-6882-13-218] [PMID: 24007270]
[90]
Dermarderosian A, Beutler JA. Review of natural products: The most complete source of natural product information. Philadelphia: Lippincott Williams & Wilkins 2001.
[91]
Fatehi M, Saleh TM, Fatehi-Hassanabad Z, Farrokhfal K, Jafarzadeh M, Davodi S. A pharmacological study on Berberis vulgaris fruit extract. J Ethnopharmacol 2005; 102(1): 46-52.
[http://dx.doi.org/10.1016/j.jep.2005.05.019] [PMID: 15993555]
[92]
Chun YT, Yip TT, Lau KL, Kong YC, Sankawa U. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmacol 1979; 10(3): 177-82.
[http://dx.doi.org/10.1016/0306-3623(79)90085-5] [PMID: 572797]
[93]
Marin - NETO JA. Maciel BC, Secches AL, Gallo L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 1988; 11(4): 253-60.
[http://dx.doi.org/10.1002/clc.4960110411] [PMID: 3365876]
[94]
Fatehi-Hassanabad Z, Jafarzadeh M, Tarhini A, Fatehi M. The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res 2005; 19(3): 222-5.
[http://dx.doi.org/10.1002/ptr.1661]
[95]
Mahdavi N, Joukar S, Najafipour H, Asadi-Shekaari M. The promising effect of barberry (Zereshk) extract against experimental pulmonary microvascular remodeling and hypertension: A comparison with sildenafil. Pharm Biol 2016; 54(3): 509-15.
[http://dx.doi.org/10.3109/13880209.2015.1050676] [PMID: 26023989]
[96]
Collins JK, Wu G, Perkins-Veazie P, et al. Watermelon consumption increases plasma arginine concentrations in adults. Nutrition 2007; 23(3): 261-6.
[http://dx.doi.org/10.1016/j.nut.2007.01.005] [PMID: 17352962]
[97]
Publications and Information Directorate, CSIR. “The Wealth of India. Raw Materials". 1992. Available From: https://www.scirp.org/(S(i43dyn45teexjx455qlt3d2q))/reference/ReferencesPapers.aspx?ReferenceID=957500
[98]
Fursa TB. Intraspecific classification of water-melon under cultivation. Kulturpflanze 1981; 29(1): 297-300.
[http://dx.doi.org/10.1007/BF02014757]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 67
Html icon 2
Find your institution